In collaboration with UCLA and MD Anderson, EarlyDx has been awarded a NIH U01 grant on "Multi-cancer early detection using cell-free DNA methylome analysis". With this award, EarlyDx will join the NIH Liquid Biopsy Consortium.
EarlyDx has been awarded a NIH SBIR Phase II contract on building a cloud-based Liquid-biopsy and Radiomics Platform for early cancer detection.
EarlyDx published Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.
Proc Natl Acad Sci USA. 2023 Jul;120(28):e2305236120.
News highlight by UCLA news, The Medical News, Drug Target Review, Medical Xpress, and Healthcare in Europe.
Check media coverage summary.
EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.
EarlyDx announced the appointment of Guanghui Hu as co-CEO.
EarlyDx Awarded an NIH SBIR Phase I Contract on the Further Development of the Cloud Computing Platform for Liquid Biopsy.
Co-founder Jasmine Zhou presented EarlyDx’s CancerRadar Technology and Clinical Data in Oral Presentation at AACR Annual Meeting 2021 on April 10, 2021.
EarlyDx Awarded an NIH SBIR Phase I Grant for Assay Development.
EarlyDx closed $5M Series Seed-1 Fundraising Led by Alpha Edison.
EarlyDx Exhibits its One-Stop Shop Bioinformatics Platform, EarlyDx-Cloud, at 2019 ASCO Annual Meeting.